# Blood Product Transfusion: Evidence-Based Thresholds

## Introduction

Blood product transfusion is one of the most common interventions in hospital medicine. Over the past two decades, landmark trials have shifted practice from liberal to **restrictive transfusion strategies**. Understanding evidence-based thresholds, indications, and risks is essential for safe and effective transfusion practice.

## Red Blood Cell Transfusion

### Hemoglobin Thresholds

| Clinical Scenario | Transfusion Threshold | Key Evidence |
|------------------|---------------------|-------------|
| Most hospitalized adults (stable) | Hb <7 g/dL | TRICC trial |
| Cardiovascular disease / symptomatic | Hb <8 g/dL | MINT trial, FOCUS trial |
| Acute coronary syndrome | Hb <8 g/dL (consider <7-8) | MINT trial (no benefit from liberal) |
| GI bleeding (hemodynamically stable) | Hb <7 g/dL | Villanueva trial |
| Septic shock (early) | Hb <7 g/dL | TRISS trial |

- Always treat the **patient, not the number**; consider symptoms, hemodynamic status, and ongoing bleeding

### Single-Unit Transfusion Policy

- Transfuse **one unit at a time** and reassess before ordering additional units
- Each unit of pRBCs raises hemoglobin by approximately **1 g/dL** in a 70 kg adult
- Single-unit transfusion reduces unnecessary exposure and conserves blood supply

![Evidence-based RBC transfusion threshold algorithm](images/rbc-transfusion-thresholds.png)

## Platelet Transfusion

### Indications and Thresholds

| Platelet Threshold | Indication |
|-------------------|-----------|
| <10,000/mcL | Prophylactic transfusion (stable, non-bleeding) |
| <20,000/mcL | Consider if fever, sepsis, or rapid decline |
| <50,000/mcL | Most invasive procedures and active bleeding |
| <100,000/mcL | Neurosurgery and ocular surgery |

- **Contraindicated** in thrombotic thrombocytopenic purpura (TTP) and heparin-induced thrombocytopenia (HIT) unless life-threatening hemorrhage

### Platelet Dosing

- One **apheresis unit** (equivalent to 6 pooled whole-blood-derived units) raises count by 30,000-50,000/mcL
- Check post-transfusion count at **1 hour** and **24 hours** to assess response
- **Platelet refractoriness**: consider HLA-matched platelets if two consecutive poor increments

## Fresh Frozen Plasma (FFP)

- Indicated for **active bleeding with coagulopathy** (INR > 1.5-2.0)
- Dose: **10-15 mL/kg** (typically 3-4 units for an adult)
- **Not indicated** for mild INR elevations without bleeding or prior to low-risk procedures
- Consider **4-factor prothrombin complex concentrate (4F-PCC)** for warfarin reversal as it provides faster correction with less volume
- FFP contains all clotting factors but requires ABO-compatible product

![Blood product selection guide for common clinical scenarios](images/blood-product-selection.png)

## Cryoprecipitate

- Rich in **fibrinogen**, Factor VIII, Factor XIII, von Willebrand factor, and fibronectin
- Primary indication: **fibrinogen < 100-150 mg/dL** in the setting of active bleeding or DIC
- Standard dose: **10 units** (one pooled dose), expected to raise fibrinogen by 50-70 mg/dL
- Also used in massive transfusion protocols and as adjunct in uremic bleeding

## Massive Transfusion Protocols

- Activated when a patient is expected to require **>10 units pRBCs in 24 hours** or **>4 units in 1 hour**
- Goal ratio of **pRBCs : FFP : platelets = 1:1:1** based on the PROPPR trial
- Early activation reduces mortality by ensuring timely availability of balanced products
- Incorporate **point-of-care coagulation testing** (TEG/ROTEM) for goal-directed therapy when available
- Monitor and treat **hypocalcemia**, hypothermia, and acidosis (the lethal triad)

## Transfusion Reactions

### Acute Reactions

- **Acute hemolytic reaction**: fever, hypotension, flank pain; caused by ABO incompatibility; stop transfusion immediately
- **Febrile non-hemolytic reaction**: most common; fever and chills without hemolysis; use leukoreduced products
- **Allergic reactions**: urticaria (mild) to anaphylaxis (severe, especially in IgA-deficient patients)
- **Transfusion-related acute lung injury (TRALI)**: non-cardiogenic pulmonary edema within 6 hours; supportive care only

### Delayed Reactions

- **Delayed hemolytic reaction**: occurs 3-28 days post-transfusion; extravascular hemolysis
- **Transfusion-associated graft-versus-host disease**: rare, fatal; prevented by irradiation of products
- **Iron overload**: in chronically transfused patients; monitor ferritin and consider chelation

![Transfusion reaction recognition and management flowchart](images/transfusion-reactions.png)

## Special Populations

- **Sickle cell disease**: use phenotypically matched, HbS-negative units; avoid overtransfusion (Hb > 10 g/dL)
- **Jehovah's Witnesses**: respect informed refusal; optimize erythropoiesis with iron, EPO, and cell salvage
- **Neonates and pediatrics**: use irradiated, CMV-negative, volume-reduced products

## Key Clinical Pearls

- A restrictive transfusion strategy (Hb < 7 g/dL) is safe and preferred for most hospitalized adults.
- Transfuse one unit at a time and reassess; avoid reflexive multi-unit orders.
- Platelet transfusion is contraindicated in TTP and HIT unless life-threatening hemorrhage is present.
- Massive transfusion protocols with balanced ratios (1:1:1) improve survival in hemorrhagic shock.
- Always report and document transfusion reactions; stop the transfusion and send required laboratory studies.

## References

1. Hebert PC, Wells G, Blajchman MA, et al. A Multicenter, Randomized, Controlled Clinical Trial of Transfusion Requirements in Critical Care (TRICC). *New England Journal of Medicine*. 1999;340(6):409-417.
2. Carson JL, Brooks MM, Abbott JD, et al. Liberal versus Restrictive Transfusion Thresholds for Patients with Symptomatic Coronary Artery Disease (MINT). *New England Journal of Medicine*. 2023;388(3):252-263.
3. Holcomb JB, Tilley BC, Baraniuk S, et al. Transfusion of Plasma, Platelets, and Red Blood Cells in a 1:1:1 vs a 1:1:2 Ratio (PROPPR). *JAMA*. 2015;313(5):471-482.
4. Kaufman RM, Djulbegovic B, Gernsheimer T, et al. Platelet Transfusion: A Clinical Practice Guideline from the AABB. *Annals of Internal Medicine*. 2015;162(3):205-213.